Fredun Pharmaceuticals Ltd Share Price – BSE

Pharmaceuticals, Small Cap

Net profit of Fredun Pharmaceuticals rose 79.67% to Rs 10.78 crore in the quarter ended March 2026 as against Rs 6.00 crore during the previous quarter ended March 2025. Sales rose 27.18% to Rs 210.41 crore in the quarter ended March 2026 as against Rs 165.44 crore during the previous quarter ended March 2025.

For the full year,net profit rose 65.25% to Rs 32.62 crore in the year ended March 2026 as against Rs 19.74 crore during the previous year ended March 2025. Sales rose 40.21% to Rs 633.33 crore in the year ended March 2026 as against Rs 451.71 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

The board of Fredun Pharmaceuticals at its meeting held on May 25, 2026, wherein the audited financial results for Q4 and FY26 were approved, has recommended the issuance of bonus shares in the ratio of 2:1, i.e. 2 fully paid-up equity shares of Rs 10 each for every 1 existing equity share of Rs 10 each, to eligible shareholders and warrant holders as on the record date, subject to shareholder approval.

Fredun Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 25 May 2026, inter alia, have recommended the final dividend of Rs 0.7 per equity Share (i.e. 7%) , subject to the approval of the shareholders.

Net profit of Fredun Pharmaceuticals rose 56.58% to Rs 11.07 crore in the quarter ended March 2026 as against Rs 7.07 crore during the previous quarter ended March 2025. Sales rose 27.18% to Rs 210.41 crore in the quarter ended March 2026 as against Rs 165.44 crore during the previous quarter ended March 2025.

For the full year,net profit rose 59.59% to Rs 33.21 crore in the year ended March 2026 as against Rs 20.81 crore during the previous year ended March 2025. Sales rose 40.21% to Rs 633.33 crore in the year ended March 2026 as against Rs 451.71 crore during the previous year ended March 2025.

Powered by Capital Market - Live News